Cardiovascular Disease Risk Factors: Epidemiology and Risk AssessmentDAHLÖF, Björn.The American journal of cardiology. 2010, Vol 105, Num 1A, issn 0002-9149, 3A-9A, SUPArticle

Prevention of stroke: new evidenceDAHLÖF, Björn.European heart journal supplements. 2009, Vol 11, Num F, issn 1520-765X, F33-F38Conference Paper

Surrogate markers for cardiovascular disease : Structural markersMANCINI, G. B; DAHLÖF, Bjorn; DIEZ, Javier et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 25, pp 22-30, issn 0009-7322, 9 p., SUPArticle

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART StudySAWADA, Takahisa; YAMADA, Hiroyuki; DAHLÖF, Björn et al.European heart journal. 2009, Vol 30, Num 20, pp 2461-2469, issn 0195-668X, 9 p.Article

Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trialWEBER, Michael A; JAMERSON, Kenneth; BAKRIS, George L et al.Lancet (British edition). 2013, Vol 381, Num 9866, pp 537-545, issn 0140-6736, 9 p.Article

Metabolic Syndrome Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLAGUPTA, Ajay K; DAHLOF, Bjorn; SEVER, Peter S et al.Diabetes care. 2010, Vol 33, Num 7, pp 1647-1651, issn 0149-5992, 5 p.Article

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm : extended observations 2 years after trial closure. CommentaryHOLDAAS, Hallvard; SEVER, Peter S; MCLNNES, Gordon et al.European heart journal. 2008, Vol 29, Num 4, issn 0195-668X, 425-426, 499-508 [12 p.]Article

Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients : Losartan intervention for end point reduction in hypertension studyNARAYAN, Puneet; PAPADEMETRIOU, Vasilios; DEVEREUX, Richard B et al.Hypertension (Dallas, Tex. 1979). 2006, Vol 47, Num 5, pp 868-873, issn 0194-911X, 6 p.Article

Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering ArmCOLLIER, David J; POULTER, Neil R; DAHLÖF, Björn et al.Journal of hypertension. 2011, Vol 29, Num 3, pp 592-599, issn 0263-6352, 8 p.Article

Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension studyCICALA, Silvana; DE SIMONE, Giovanni; GERDTS, Eva et al.Journal of hypertension. 2010, Vol 28, Num 6, pp 1134-1140, issn 0263-6352, 7 p.Article

The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone : Results from ASCOTLINDGREN, Peter; BUXTON, Martin; KAHAN, Thomas et al.PharmacoEconomics (Auckland). 2009, Vol 27, Num 3, pp 221-230, issn 1170-7690, 10 p.Article

Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE study)BOMAN, Kurt; OLOFSSON, Mona; DAHLÖF, Björn et al.The American journal of cardiology. 2005, Vol 95, Num 2, pp 280-283, issn 0002-9149, 4 p.Article

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)SEVER, Peter S; POULTER, Neil R; DAHLÖF, Bjorn et al.The American journal of cardiology. 2005, Vol 96, Num 5, pp 39F-44F, issn 0002-9149, SUPConference Paper

Association of Heart Failure Hospitalizations With Combined Electrocardiography and Echocardiography Criteria for Left Ventricular HypertrophyGERDTS, Eva; OKIN, Peter M; BOMAN, Kurt et al.American journal of hypertension. 2012, Vol 25, Num 6, pp 678-683, issn 0895-7061, 6 p.Article

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-riskGUPTA, Ajay K; NASOTHIMIOU, Efthimia G; CHANG, Choon L et al.Journal of hypertension. 2011, Vol 29, Num 10, pp 2004-2013, issn 0263-6352, 10 p.Article

All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophyOKIN, Peter M; KJELDSEN, Sverre E; JULIUS, Stevo et al.European heart journal. 2010, Vol 31, Num 18, pp 2271-2279, issn 0195-668X, 9 p.Article

Greater Regression of Electrocardiographic Left Ventricular Hypertrophy During Hydrochlorothiazide Therapy in Hypertensive PatientsOKIN, Peter M; HILLE, Darcy A; KJELDSEN, Sverre E et al.American journal of hypertension. 2010, Vol 23, Num 7, pp 786-793, issn 0895-7061, 8 p.Article

Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE Study)ZABALGOITIA, Miguel; BERNING, Jens; KOREN, Michael J et al.The American journal of cardiology. 2001, Vol 88, Num 6, pp 646-650, issn 0002-9149Article

Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients : The Losartan Intervention For Endpoint reduction (LIFE) in hypertension studyOKIN, Peter M; DEVEREUX, Richard B; JERN, Sverker et al.Hypertension (Dallas, Tex. 1979). 2000, Vol 36, Num 5, pp 766-773, issn 0194-911XArticle

Left atrial size and risk of major cardiovascular events during antihypertensive treatment : Losartan intervention for endpoint reduction in hypertension trialGERDTS, Eva; WACHTELL, Kristian; OMVIK, Per et al.Hypertension (Dallas, Tex. 1979). 2007, Vol 49, Num 2, pp 311-316, issn 0194-911X, 6 p.Article

Relation of echocardiographic left ventricular mass and hypertrophy to Persistent electrocardiographic left ventricular hypertropy in hypertensive patients: The LIFE studyOKIN, Peter M; DEVEREUX, Richard B; JERN, Sverker et al.American journal of hypertension. 2001, Vol 14, Num 8, pp 775-782, issn 0895-7061, 1Article

Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillationOKIN, Peter M; GERDTS, Eva; WACHTELL, Kristian et al.Journal of hypertension. 2010, Vol 28, Num 7, pp 1534-1540, issn 0263-6352, 7 p.Article

Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)POULTER, Neil R; DOBSON, Joanna E; SEVER, Peter S et al.Journal of the American College of Cardiology. 2009, Vol 54, Num 13, pp 1154-1161, issn 0735-1097, 8 p.Article

Change in Pulse Pressure/Stroke Index in Response to Sustained Blood Pressure Reduction and Its Impact on Left Ventricular Mass and Geometry Changes : the Life StudyPALMIERI, Vittorio; BELLA, Jonathan N; GERDTS, Eva et al.American journal of hypertension. 2008, Vol 21, Num 6, pp 701-707, issn 0895-7061, 7 p.Article

Cost effectiveness of losartan in patients with hypertension and LVH : an economic evaluation for Sweden of the LIFE trialJÖNSSON, Bengt; CARIDES, George W; BURKE, Thomas A et al.Journal of hypertension. 2005, Vol 23, Num 7, pp 1425-1431, issn 0263-6352, 7 p.Article